SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- PARKINSON DISEASE (Disorder)
- Advanced Parkinson's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Serina Therapeutics
- Last updated on ClinicalTrials.gov
- June 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Velocity Clinical Research · Hallandale, FL
- K2 Medical Research LLC · Maitland, FL
Michigan · 1
- Quest Research Institute · Farmington Hills, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.